Christopher Bunker
Company: Alamar Biosciences Inc.
Job title: Vice President, Biopharma Business Development
Seminars:
NULISA: Ultra-sensitive & Multiplex Immunoassay Platform for Fluid Biomarkers in CNS Disease 9:30 am
New biomarker assay technology, NULISA™ – with ultra-sensitive femtogram level detection with proprietary background suppression technology Unique NULISA CNS Disease Panel detecting nearly 120 critical biomarkers covering diverse neurological diseases Ultra-sensitive NULISA technology holds great promise to enable early detection and monitoring of neurodegenerative diseases to aid in new therapeutic development.Read more
day: Day One